New Drug Approvals: April 2006

Date of Approval: April 6, 2006

Company: Shire Pharmaceuticals Group plc / Noven Pharmaceuticals, Inc.

Treatment for Attention Deficit Hyperactivity Disorder (ADHD)

Daytrana is a once daily transdermal patch formulation of methylphenidate indicated for the treatment of attention deficit hyperactivity disorder (ADHD).

Date of Approval: April 13, 2006

Company: Farmacon-IL, LLC

Treatment for Patent Ductus Arteriosus

NeoProfen is an intravenous formulation of ibuprofen lysine indicated to close a clinically significant patent ductus arteriosus (PDA) in premature infants, who are no more than 32 weeks gestational age when usual medical management is ineffective.

Company: Alkermes, Inc.

Treatment for Alcohol Dependence

Date of Approval: April 28, 2006

Company: Genzyme Corp.

Treatment for Pompe disease

Myozyme is a recombinant formulation of the human enzyme acid alpha-glucosidase (GAA) indicated for use in patients with Pompe disease (GAA deficiency), a debilitating and often fatal muscle disorder.